Researchers at the University of Wisconsin, including former OCRF grantee Stephen Rose, MD, conducted a qualitative research study looking at how patients with recurrent ovarian cancer experience humor to gain insight into the feasibility of using humor as a “therapeutic adjunct.” The study, which was published in the March 2013 issue of the International Journal … Continued
Ovarian cancer survivor Susan Leighton reports on her experience at the American Association of Cancer Researchers meeting, which took place in April 2013. For the second year in a row I had the privilege of being selected to attend the Scientist-Survivor Program (SSP) of the American Association of Cancer Researchers. The SSP program was established … Continued
Earlier this month at the annual meeting of the American Academy of Cancer Research, OCRF grantee Joyce Liu, MD, MPH presented research showing that 20% of women with platinum-resistant ovarian cancer responded to an experimental drug that targets a protein common in ovarian cancer. The small clinical trial is the first to show results from … Continued
In a small study presented at the annual meeting of the American Association of Cancer Research earlier this month, researchers from the University of Pennsylvania reported success with a new two-step immunotherapy approach to treating advanced ovarian cancer when combined with chemotherapy. The process begins with treatment with a personalized vaccine, which is created from … Continued
Women who had surgery to treat their endometriosis also lowered their risk of developing ovarian cancer. A study of approximately 600 Swedish women found that those who either had one ovary removed or had surgery to remove endometriotic tissue had a 20 to 42 percent lower risk of developing ovarian cancer. See the abstract here … Continued
In a new study of over 47,000 women with ovarian cancer, researchers found disparities in the quality of ovarian cancer care and survival according to race and socioeconomic status. Not receiving care adherent with National Comprehensive Cancer Network guidelines was a predictor of inferior survival. Women who were black, on Medicare, or uninsured were less … Continued
A study of 231 cancer patients found that the use of duloxetine (Cymbalta) reduced chemotherapy induce peripheral neuropathy. Patients either recieved Cymbalta or a placebo; in the Cymbalta arm, 59% of patients had an improvement in symptoms, whereas in the placebo arm only 38% of patients had an improvement in symptoms. The abstract is available … Continued
According to research published in March 6 in the journal Nature, researchers have discovered a possible origin of epithelial ovarian cancer. The origin of ovarian cancer is unclear, making the development of a method of early detection very difficult. Scientists know that some epithelial cancers occur in transitional zones between two types of epithelium (layers of … Continued
On Tuesday, April 2, the U.S. Preventive Services Task Force (USPSTF) released its draft recommendation statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer. The USPSTF recommends that primary care providers screen women who have family members with breast or ovarian cancer with one of several screening tools designed to identify a … Continued
Research published today in the Journal of the American Medical Association showed that the depression and anxiety drug duloxetine effectively treated painful chemotherapy-induced peripheral neuropathy. Chemotherapy-induced peripheral neuropathy occurs in roughly 20% to 40% of patients treated with chemotherapy agents such as taxanes, platinums, and vinca alkaloids. The condition can persist for years following treatment … Continued
At this year’s Society of Gynecologic Oncology (SGO) Annual Meeting, numerous presentations and posters explored issues related to ovarian cancer, some of which are summarized below. This year’s SGO Annual Meeting theme, “Embrace the Past, Revolutionize the Future,” was especially fitting given the changing landscape of ovarian cancer treatment. As the Cancer Genome Atlas reveals … Continued
Dave Brown is walking for 9 months and nearly 3,000 miles to raise awareness and support.
Get email updates about research news, action alerts, and ways to join the fight.
